440204
LY 294002
InSolution, ≥98%, 10 mM, reversible and specific inhibitor of PI 3-kinase
Sinónimos:
InSolution LY 294002, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, BRD2 Inhibitor IV, BRD3 Inhibitor III, BRD4 Inhibitor IV
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C19H17NO3
Número CAS:
Peso molecular:
307.34
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
liquid
Quality level:
Storage condition:
OK to freeze, protect from light
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
assay
≥98% (HPLC)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
shipped in
wet ice
storage temp.
−20°C
SMILES string
N4(CCOCC4)c1[o]c2c([c](c1)=O)cccc2c3ccccc3
InChI
1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
InChI key
CZQHHVNHHHRRDU-UHFFFAOYSA-N
General description
Cell permeable: Yes
Primary Target: phosphatidylinositol 3-kinase
Product competes with ATP.
Reversible: Yes
Target IC50: 1.4 µM against phosphatidylinositol3-kinase
LY294002 is a chemical compound known for its potentinhibitory effects on a variety of proteins, particularly as a strong inhibitorof phosphoinositide 3-kinases (PI3Ks). While it is frequently utilized in research related to the PI3K/AKT signaling pathway, LY294002 is generallyregarded as a non-selective tool for investigating PI3K functions. This flavonoid derivative acts as a competitive andreversible inhibitor of the ATP binding site of PI3K, exhibiting an IC50 approximately 500-fold higher than that of wortmannin, at 1.4 μM. LY294002 doesnot inhibit several ATP-dependent enzymes, including PI4K, EGF receptor tyrosinekinase, c-src, MAP kinase, S6 kinase, diacylglycerol kinase, protein kinase A, protein kinase C, and ATPase. It acts as an antagonist of the aryl hydrocarbonreceptor (AHR), a ligand-activated transcription factor. By binding to AHR, LY294002 inhibits transcriptional activation, thereby preventing gene expression.
Primary Target: phosphatidylinositol 3-kinase
Product competes with ATP.
Reversible: Yes
Target IC50: 1.4 µM against phosphatidylinositol3-kinase
LY294002 is a chemical compound known for its potentinhibitory effects on a variety of proteins, particularly as a strong inhibitorof phosphoinositide 3-kinases (PI3Ks). While it is frequently utilized in research related to the PI3K/AKT signaling pathway, LY294002 is generallyregarded as a non-selective tool for investigating PI3K functions. This flavonoid derivative acts as a competitive andreversible inhibitor of the ATP binding site of PI3K, exhibiting an IC50 approximately 500-fold higher than that of wortmannin, at 1.4 μM. LY294002 doesnot inhibit several ATP-dependent enzymes, including PI4K, EGF receptor tyrosinekinase, c-src, MAP kinase, S6 kinase, diacylglycerol kinase, protein kinase A, protein kinase C, and ATPase. It acts as an antagonist of the aryl hydrocarbonreceptor (AHR), a ligand-activated transcription factor. By binding to AHR, LY294002 inhibits transcriptional activation, thereby preventing gene expression.
Application
LY294002 has been used as a phosphatidylinositol3-kinase (PI3K) inhibitor:
- to induce viral reactivation in a model ofherpes simplex virus type 1 (HSV-1) latency
- to investigate its effects on transforminggrowth factor (TGF)-β1-induced differentiation of cat corneal fibroblasts
- to investigate its role in the insulin-like growthfactor I (IGF-1) signaling pathway and on the phosphorylation of glycogensynthase kinase-3β (GSK-3β)
Biochem/physiol Actions
Cell permeable: yes
Primary Target
phosphatidylinositol 3-kinase
phosphatidylinositol 3-kinase
Product competes with ATP.
Reversible: yes
Target IC50: 1.4 µM against phosphatidylinositol 3-kinase
Packaging
Packaged under inert gas
Physical form
A 10 mM (1 mg/325 µl) solution of LY 294002 (Cat. No. 440202) in DMSO.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Other Notes
Dittman, A., et al. 2013. ACS Chem. Biol.9, 495.
Baumann, P., and West, S.C. 1998. Proc. Natl. Acad. Sci. USA95, 14066.
Cardone, M.H., et al. 1998. Science282, 1318.
Vlahos, C.J., et al. 1995. J. Immunol.154, 2413.
Yano, H., et al. 1995. Biochem. J.312, 145.
Vlahos, C.J., et al. 1994. J. Biol. Chem.269, 5241.
Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.
Baumann, P., and West, S.C. 1998. Proc. Natl. Acad. Sci. USA95, 14066.
Cardone, M.H., et al. 1998. Science282, 1318.
Vlahos, C.J., et al. 1995. J. Immunol.154, 2413.
Yano, H., et al. 1995. Biochem. J.312, 145.
Vlahos, C.J., et al. 1994. J. Biol. Chem.269, 5241.
Selected Citations
Lee, J., et al. 2009. Cell Stem Cell5, 76.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Irritant (B)
Clase de almacenamiento
10 - Combustible liquids
wgk
WGK 1
flash_point_f
188.6 °F - (refers to pure substance)
flash_point_c
87 °C - (refers to pure substance)
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Xiaohua Wu et al.
Molecules (Basel, Switzerland), 26(13) (2021-07-03)
Astragalus membranaceus is a famous herb found among medicinal and food plants in East and Southeastern Asia. The Nrf2-ARE assay-guided separation of an extract from Jing liqueur led to the identification of a nontoxic Nrf2 activator, methylnissolin-3-O-β-d-glucopyranoside (MNG, a component
Abdelkader Essafi et al.
Methods in molecular biology (Clifton, N.J.), 462, 201-211 (2009-01-24)
This chapter describes methods for studying downstream events of the PI3K/Akt signaling cascade, focusing on the FoxO transcription factors. These approaches also represent alternative means for gauging the phosphoinositide-3 kinase/Akt activity. We describe protocols for the fractionation of cytoplasmic and
Anna Bellizzi et al.
Molecular therapy. Nucleic acids, 35(3), 102282-102282 (2024-08-23)
Although our understanding of herpes simplex virus type 1 (HSV-1) biology has been considerably enhanced, developing therapeutic strategies to eliminate HSV-1 in latently infected individuals remains a public health concern. Current antiviral drugs used for the treatment of HSV-1 complications